ReviewCureus2026
Bridging the Gap in Sjögren's Disease: A Comprehensive Review of Unmet Needs, Diagnostic Challenges, and Emerging Therapeutic Strategies.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren's disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration of exocrine glands and substantial extraglandular involvement. It is widely recognized as one of the most prevalent systemic rheumatic autoimmune diseases; however, patients experience a diagnostic delay averaging roughly five to six years from symptom onset, during which irreversible glandular and systemic damage may accumulate. No disease-modifying therapy is currently approved for SjD, and management remains largely symptomatic, centered on artificial tears, sialogogues, and hydroxychloroquine, none of which reliably arrest systemic immunopathology. This review synthesizes unmet needs across the diagnostic, symptomatic, and therapeutic domains of SjD, with particular attention to the persistent burden of fatigue, cognitive dysfunction, chronic pain, and lymphoproliferative risk. It examines the clinimetric utility of the European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) as complementary tools that capture systemic organ-based activity and patient-reported symptom burden, respectively. Their growing role as primary endpoints in modern clinical trials is also discussed. Finally, emerging therapeutic strategies are highlighted, including B-cell/BAFF-receptor-targeted ianalumab, the FcRn blocker nipocalimab, and the CD40-CD40L pathway inhibitor dazodalibep, which have demonstrated promising efficacy signals in randomized controlled trials. Improving outcomes in SjD will require earlier recognition, more consistent application of validated outcome measures in routine practice, and rational adoption of emerging immunoselective therapies guided by biomarker-based patient stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.